BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25519148)

  • 21. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
    Shen J; Hong Y; Zhao Q; Zhang JL
    Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
    Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
    Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
    Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.
    Miyake R; Yamanaka S; Matsubara S; Mabuchi S
    Anticancer Res; 2021 Sep; 41(9):4277-4285. PubMed ID: 34475047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
    Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
    Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
    Dasmahapatra GP; Didolkar P; Alley MC; Ghosh S; Sausville EA; Roy KK
    Clin Cancer Res; 2004 Aug; 10(15):5242-52. PubMed ID: 15297428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
    Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
    Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S; Chang H; Deng S; Fan D
    Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
    Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
    Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells.
    Li X; Luwor R; Lu Y; Liang K; Fan Z
    Oncogene; 2006 Jan; 25(4):525-35. PubMed ID: 16170346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
    Zhao JX; Liu H; Lv J; Yang XJ
    Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
    Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
    Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.